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Abstract Increased plasma levels of human lipoprotein(a)
(Lp(a)) are highly correlated with the development of athero-
sclerotic lesions. During our study, we investigated the effects of
native and hypochlorite oxidized lipoprotein(a) (ox-Lp(a)) on
nitric oxide production by the inducible nitric oxide synthase
(iNOS) in lipopolysaccharide/interferon stimulated mouse
macrophages (J774A.1). Ox-Lp(a) (0^2 Wg/ml) induces a dose
dependent inhibition of inducible nitric oxide synthesis. iNOS
protein expression showed a dose dependent reduction as revealed
by immunoblotting when cells were incubated with increasing
amounts of ox-Lp(a). Ox-Lp(a) decreases iNOS mRNA
synthesis as shown by reverse transcription-polymerase chain
reaction. Ox-Lp(a) induced iNOS inhibition might contribute to
the development of atherosclerotic lesions by reducing the anti-
atherogenic effects of nitric oxide. ß 2000 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
The plasma concentration of human lipoprotein(a) (Lp(a))
is highly correlated with coronary artery disease [1]. Lp(a)
consists of low density lipoprotein (LDL) with the additional
protein component, apolipoprotein(a) (apoLp(a)), a homolog
of plasminogen [2]. The protein moiety of Lp(a), apoLp(a),
consists of two apoproteins, apo(a) and apoB-100, linked by
one or more disul¢de bonds(s). Apo(a), the protein unique to
Lp(a), exists in polymorphic forms that exhibit di¡erent ap-
parent molecular weights in the range of 419^838 kDa [1].
It has been shown that Lp(a) accumulates in the arterial
wall, partly in the form of lipoprotein-like particles, therefore
contributing to plaque formation and coronary heart disease
[3^5]. The amount of apo(a) deposition in cerebral vessels
correlated well with the degree of cerebral atherosclerosis
[6]. Lp(a) has been detected both extracellularly and within
foam cells [7]. Oxidative modi¢cation of Lp(a) results in its
recognition and uptake by scavenger receptors on macro-
phages [8^10]. As these receptors are not down-regulated by
the intracellular cholesterol level, the macrophages transform
to foam cells [11].
The mechanisms by which Lp(a) may accelerate the devel-
opment of atherosclerotic lesions remain obscure. Lp(a) and
apoLp(a) enhance proliferation of human vascular smooth
muscle cells (VSMC) in culture [12]. This has been explained
by inhibiting activation of plasminogen to plasmin, thus
blocking the proteolytic activation of transforming growth
factor L (TGF-L), an autocrine inhibitor of human VSMC
proliferation. Oxidized Lp(a) (ox-Lp(a)) has been shown to
impair nitric oxide (NO) mediated, endothelium dependent
dilation in renal arteries, probably by increasing superoxide
anion production and by enhanced inactivation of NO [13].
NO is synthesized from L-arginine by the L-arginine^NO
pathway [14]. A family of enzymes, termed the nitric oxide
synthases (NOS), catalyze the formation of NO and citrulline
from L-arginine, O2, and NADPH [15]. The inducible isoform
of NOS (NOS-2 or iNOS) generates large amounts of NO
over a prolonged period of time through a Ca2 independent
pathway [16]. iNOS expression has been observed in many
cells, including murine macrophages [17], endothelial cells
[18], smooth muscle cells [19], and cardiac myocytes [20].
NO inhibits proliferation of VSMCs, mesangial cells, and ¢-
broblasts [21].
The development of atherosclerotic lesions as a conse-
quence of decreased NO synthesis has been reported [22,23].
The anti-atherogenic properties of NO include antiprolifera-
tive actions such as the inhibition of smooth muscle and T-cell
proliferation [24], reduced neutrophil adhesion [25,26], inhibi-
tion of platelet activation [27], and the reduction of endothe-
lial hyperpermeability [28]. The low release of NO, both basal
and stimulated, has been reported for atherosclerotic vessels
[29]. Atherosclerosis associated factors with the ability to re-
duce iNOS include oxidatively modi¢ed LDLs [30] and heat
shock proteins [31]. In situ hybridization con¢rmed that the
iNOS is present in macrophages, foam cells, and VSMCs of
atherosclerotic lesions [32^35]. However, the e¡ects of ox-
Lp(a) on inducible NO synthesis have not yet been investi-
gated.
Using interferon Q (IFN-Q)/lipopolysaccharide (LPS) stimu-
lated macrophages we examined the e¡ects of native Lp(a)
and hypochlorite (HOCl) oxidized Lp(a) on inducible NO
synthesis. During our experiments HOCl oxidized Lp(a) was
used because HOCl might be released from activated neutro-
phils in vivo [36], and the occurrence of HOCl oxidized lipo-
protein within atherosclerotic lesion has been demonstrated
[37]. The inhibition of inducible NO synthesis by ox-Lp(a)
might initiate macrophage proliferation since NO decreases
cell proliferation by increasing the rate of apoptosis [38].
Thus, ox-Lp(a) induced iNOS inhibition might be relevant
for the development of atherosclerotic lesions.
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2. Materials and methods
2.1. Materials
[3H]L-Arginine (68 Ci/mmol) was supplied by Amersham Corp.,
Arlington Heights, IL, USA. Recombinant mouse IFN-Q was pur-
chased from Gibco BRL, Gaithersburg, MD, USA. Rabbit anti-
iNOS polyclonal antibody and puri¢ed iNOS protein was supplied
by Calbiochem, San Diego, CA, USA. Cell culture materials, Esche-
richia coli LPS serotype 055:B5, Lp(a), and all other chemicals were
obtained from Sigma Chemical Co., St. Louis, MO, USA.
2.2. Cell culture
The mouse monocyte/macrophage cell line J774A.1 (ATCC TIB 67)
was cultured in Dulbecco’s modi¢ed Eagle’s medium (DMEM) sup-
plemented with 10% fetal bovine serum, 25 mM HEPES, 2 mM glu-
tamine, 100 U/ml penicillin and 100 Wg/ml streptomycin at 37‡C, 5%
CO2, and 95% humidity. Cells were studied between passages 7 and
20. Cells were seeded in 24 well dishes at a density of 2U105 cells/well,
stimulated by IFN-Q (10 U/ml) and LPS (2 Wg/ml), and incubated
either with or without the indicated lipoproteins for 24 h.
2.3. Nitrite analysis
Nitrite was determined spectrophotometrically using the Griess re-
agent (0.5% sulfanilic acid, 0.002% N-1-naphthyl-ethylenediamine di-
hydrochloride, 14% glacial acetic acid) in supernatants. Absorbance
was measured at 550 nm with baseline correction at 650 nm and
nitrite concentration was determined using sodium nitrite as a stan-
dard [39].
2.4. Oxidation of Lp(a)
The preparation of HOCl oxidized Lp(a) was performed as de-
scribed previously [36,40]. The molar excess of HOCl over Lp(a)
was in the range of 400^600. After allowing the HOCl reagent to react
with Lp(a) for 15 min on ice, Lp(a) was passed over a size exclusion
column (Bio-Rad 10DG) equilibrated with phosphate bu¡ered saline
containing 100 WM EDTA to remove excess reagent. Agarose gel
electrophoresis showed increased electrophoretic mobility (1.4-fold)
of ox-Lp(a) particles.
2.5. Arginine transport
Arginine uptake by macrophages was measured by adding [3H]L-
arginine (68 Ci/mmol, 0.2 WCi/well) directly to the medium after a 24 h
incubation with or without ox-Lp(a) as indicated. After 60 min the
medium was aspirated and the cells were washed twice with 500 Wl ice-
cold phosphate bu¡ered saline. Cells were lysed with 200 Wl of
300 mM sodium hydroxide containing 1% sodium dodecyl sulfate
(SDS). Samples were aspirated and subjected to liquid scintillation
counting.
2.6. Protein determination
Protein was determined according to the method of Bradford [41]
using bovine serum albumin as standard.
2.7. Western blotting for iNOS
Cells were lysed in ice-cold bu¡er containing 25 mM monosodium
phosphate (pH 7.4), 75 mM NaCl, 5 mM EDTA, 1% Triton X-100,
100 Wg/ml phenylmethylsulfonyl £uoride, 10 Wg/ml antipain, 10 Wg/ml
leupeptin, 10 Wg/ml pepstatin, 20 Wg/ml aprotinin, and 10 Wg/ml tryp-
sin inhibitor and centrifuged at 50 000Ug for 20 min at 4‡C. The
cytosolic proteins (20 Wg per lane) were separated by 8% SDS^poly-
acrylamide gel electrophoresis. Proteins were transferred to nitrocellu-
lose ¢lters, and then immunoblotted with a rabbit anti-iNOS poly-
clonal antibody at a 1:1000 dilution. Anti-rabbit horseradish
peroxidase conjugated antibody was used as a secondary antibody
at a dilution of 1:2500. The blots were detected with the enhanced
chemiluminescence method and exposed to photographic ¢lm.
2.8. Semiquantitative reverse transcription-polymerase chain reaction
(RT-PCR)
Total RNA was isolated using the guanidinium thiocyanate method
[42]. To determine the RNA concentration the absorption at 260, 280,
and 320 nm was measured photometrically (UV/Vis Spectrophotom-
eter Lambda 2, Perkin-Elmer, Norwalk, CT, USA). Single stranded
cDNA synthesis was carried out on 2 Wg of total RNA primed with
oligo(dT)12ÿ18 (Pharmacia, Freiburg, Germany) using murine leuke-
mia virus reverse transcriptase (MMLV-RT; MBI Fermentas, Vilnius,
Lithuania) at 37‡C for 60 min. Reactions were stopped by heating for
5 min at 70‡C. iNOS cDNA was subjected to DNA ampli¢cation by
PCR using 0.5 units of Taq DNA polymerase (MBI) with oligonu-
cleotide primers complementary to murine iNOS cDNA (MWG-Bio-
tec, Ebersberg, Germany) at a ¢nal concentration of 0.25 WM. Reac-
tion mixtures were subjected to the following conditions in a PE 2400
DNA thermal cycler (Perkin-Elmer): denaturing at 94‡C for 30 s,
annealing at 55‡C for 35 s, and extension at 72‡C for 35 s. After
35 cycles, the reaction mixture was cooled down to 4‡C. The primers
for iNOS were 5P-CTA AGA GTC ACC AAA ATG GCT CCC-3P
(sense) and 5P-ACC AGA GGC AGC ACA TCA AAG C-3P (anti-
sense). The expected product length was 775 bp. As a control, we used
the following primers for the ‘housekeeping gene’ L-actin: 5P-ATG
GTG GGA ATG GGT CAG AAG GAC-3P(sense) and 5P-CTC
TTT GAT GTC ACG CAC GAT TTC-3P (antisense). PCR condi-
tions were as above with the exception that only 30 cycles were run.
The expected product length was 513 bp. All PCR reactions were in
linear range. Final PCR products were separated on a 1.2% agarose
gel and detected by ethidium bromide staining. Semiquantitative esti-
mation was done by comparing mRNA expression of iNOS to L-actin
represented by the amount of the PCR product formed.
2.9. Data analysis
Each experimental result as shown in the ¢gures is the mean þ S.D.
of at least three measurements. When S.D. is not displayed, it is
smaller than the size of the symbol. Statistical analyses were per-
formed by use of ANOVA followed by Student’s t-tests for unpaired
data. Statistical signi¢cance was de¢ned as P6 0.05.
3. Results
3.1. Inhibition of inducible NO synthesis by ox-Lp(a)
Activated J774A.1 cells released large amounts of nitrite
into the culture medium (71 þ 8.3 nmol nitrite/mg protein
within 24 h). Incubation of activated J774A.1 cells with ox-
Lp(a) (0^2 Wg/ml) was associated with a dose dependent re-
duction in NO production (Fig. 1). Incubations with native
Lp(a) revealed no inhibition of NO synthesis. Measurements
of cytotoxicity were performed since toxic e¡ects of oxidized
lipoproteins towards various cell species have been described.
At the concentrations of ox-Lp(a) or native Lp(a) used during
our study, cell viabilities were s 95% as measured by trypan
Fig. 1. Dose dependent inhibition of NO production by HOCl ox-
Lp(a) in J774A.1 macrophages. Cells were activated with 10 U/ml
IFN-Q and 2 Wg/ml LPS and incubated with increasing amounts (0^
2 Wg/ml ¢nal concentration) of oxidized (b) or native (a) Lp(a) as
indicated for 24 h. After 24 h the culture media were collected and
assayed for nitrite as described in Section 2. Each data point shows
the mean of triplicate measurements. Error bars show the standard
deviation. P6 0.01 or smaller for incubations containing 0.5^2 Wg/
ml ox-Lp(a) when compared to controls without ox-Lp(a). Di¡eren-
ces between the incubations containing native Lp(a) were not statis-
tically signi¢cant.
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blue exclusion. To exclude that ox-Lp(a) interferes with de-
tection of nitrite by the Griess reaction or in£uences the
stability of NO, we incubated ox-Lp(a) (0^2 Wg/ml) with the
NO donor linsidomine (2 mM) for 24 h at room temperature.
Ox-Lp(a) had no statistically signi¢cant e¡ect on the nitrite
measured (122 þ 11 WM nitrite without ox-Lp(a) vs. 131 þ 12
WM nitrite for 1 Wg/ml ox-Lp(a) and 138 þ 8 WM nitrite for
2 Wg/ml ox-Lp(a)). We conclude, therefore, that ox-Lp(a) does
not scavenge NO or interfere with the detection of nitrite by
the Griess reaction.
3.2. E¡ects of ox-Lp(a) on arginine transport
To investigate whether ox-Lp(a) induced inhibition of NO
production was associated with a decreased arginine uptake,
J774A.1 cells were incubated with [3H]L-arginine as described
in Section 2. Arginine transport into the cells was not signi¢-
cantly reduced when incubated with increasing amounts (0^
2 Wg/ml ¢nal concentration) of ox-Lp(a) (data not shown). It
can be concluded that inhibition of NO synthesis is not a
consequence of reduced cellular arginine uptake.
3.3. Inhibition of iNOS protein expression by ox-Lp(a)
Fig. 2 shows the Western blot analysis of iNOS in J774A.1
cells. IFN-Q/LPS stimulated macrophages were cultured with
increasing amounts of HOCl oxidized Lp(a) (0^2 Wg/ml) for
24 h. Immunoblotting shows a band with an estimated mo-
lecular mass of 130 kDa (the known molecular mass of iNOS)
in stimulated J774A.1 mouse macrophages. An identical mo-
lecular mass was determined by blotting against puri¢ed iNOS
protein. iNOS protein showed a dose dependent reduction
when cells were incubated with 0^2 Wg/ml HOCl oxidized
Lp(a). In contrast, actin (43 kDa) levels remained unchanged
during incubations of IFN-Q/LPS stimulated J774A.1 mouse
macrophages with increasing amounts of ox-Lp(a). This
shows that ox-Lp(a) does not cause a generalized decrease
in protein expression.
3.4. E¡ects of ox-Lp(a) on iNOS mRNA expression
Fig. 3 shows the RT-PCR analysis of iNOS mRNA in
J774A.1 cells. IFN-Q/LPS stimulated mouse macrophages
were incubated with 0^2 Wg/ml HOCl oxidized Lp(a) for
24 h. iNOS mRNA (775 bp) was reduced by ox-Lp(a) in a
dose dependent manner (lanes 1^5). Native Lp(a) (lane 6) had
no e¡ect on iNOS mRNA level. Semiquantitative estimation
was done by comparing mRNA expression of iNOS to L-actin
represented by the amount of the PCR product formed. Our
data show that ox-Lp(a) inhibits iNOS expression on a tran-
scriptional level.
4. Discussion
This paper shows that HOCl oxidized Lp(a), but not native
Lp(a), inhibits inducible NO synthesis in IFN-Q/LPS stimu-
lated J774A.1 mouse macrophages in a dose dependent man-
ner. The ox-Lp(a) induced iNOS (EC 1.14.13.39) inhibition
was associated with a dose dependent reduction of iNOS pro-
tein as revealed by immunoblotting when cells were incubated
with 0^2 Wg/ml HOCl oxidized Lp(a). In contrast, actin levels
remained unchanged during incubations of IFN-Q/LPS stimu-
lated J774A.1 mouse macrophages with increasing amounts of
ox-Lp(a). This shows that ox-Lp(a) does not cause a general-
ized decrease in protein expression. iNOS mRNA was reduced
by ox-Lp(a) in a dose dependent manner. Native Lp(a) had no
Fig. 2. Immunoblotting against iNOS. IFN-Q/LPS stimulated
J774A.1 mouse macrophages were cultured with increasing amounts
of HOCl oxidized Lp(a) (0^2 Wg/ml) for 24 h. Western blotting was
performed as described in Section 2. Lane 1: control incubations of
stimulated J774A.1 mouse macrophages without ox-Lp(a); lanes 2^
4: incubations containing 0.5^2 Wg/ml ox-Lp(a). Immunoblotting
identi¢ed a band with an estimated molecular mass of 130 kDa
(iNOS) in stimulated J774A.1 mouse macrophages. iNOS protein
was markedly reduced in cells incubated with ox-Lp(a) (lanes 2^4).
In contrast, actin (43 kDa) levels remained unchanged during incu-
bations of IFN-Q/LPS stimulated J774A.1 mouse macrophages with
increasing amounts of ox-Lp(a).
Fig. 3. E¡ects of ox-Lp(a) on iNOS mRNA expression (RT-PCR).
J774A.1 mouse macrophages were incubated with 0^2 Wg/ml HOCl
oxidized Lp(a) or 2 Wg/ml native Lp(a) and IFN-Q/LPS for 24 h.
RNA was extracted and analyzed as described in Section 2, single
stranded cDNA synthesis was performed, and DNA was ampli¢ed
by PCR using speci¢c primers for iNOS and actin. iNOS mRNA
(775 bp) was reduced by ox-Lp(a) in a dose dependent manner
(lane 1^5). Native Lp(a) (lane 6) had no e¡ect on iNOS mRNA lev-
el. Semiquantitative estimation was done by comparing mRNA ex-
pression of iNOS to L-actin represented by the amount of the PCR
product formed.
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e¡ect on iNOS mRNA level. This shows that ox-Lp(a) inhib-
its iNOS expression on a transcriptional level.
During our experiments HOCl was used for Lp(a) oxida-
tion because its physiological relevance has been emphasized
[37]. HOCl is an oxidant produced from H2O2 and chloride
by myeloperoxidase (MPO, EC 1.11.1.7). MPO is present in
its active form in human atherosclerotic lesions and might be
released from activated neutrophils in vivo [43]. HOCl oxi-
dized Lp(a) and HOCl oxidized LDL are both e¡ective li-
gands for loading mouse peritoneal macrophages in vitro
[36]. HOCl oxidized proteins have been demonstrated in hu-
man atherosclerotic lesions using monoclonal antibodies and
were predominantly found in monocytes/macrophages,
smooth muscle cells, and endothelial cells [37]. Oxidative mod-
i¢cation of Lp(a) results in its recognition and uptake by the
macrophage scavenger receptor system [8]. As these receptors
are not down-regulated by the intracellular cholesterol level,
the macrophages transform to foam cells [11].
Lp(a) plasma levels are strongly correlated with the devel-
opment of atherosclerotic lesions. It has been shown that
Lp(a) accumulates in the arterial wall, partly in the form of
lipoprotein-like particles, therefore contributing to plaque for-
mation and coronary heart disease [3^5]. The amount of
apo(a) deposition in cerebral vessels correlates well with the
degree of cerebral atherosclerosis [6]. Lp(a) has been detected
both extracellularly and within foam cells [7]. The mechanisms
by which Lp(a) may accelerate the development of athero-
sclerotic lesions remain obscure. Lp(a) and apoLp(a) enhance
proliferation of human VSMCs in culture [12]. This has been
explained by inhibiting the activation of plasminogen to plas-
min, thus blocking the proteolytic activation of TGF-L, an
autocrine inhibitor of human VSMC proliferation.
Formation of NO by the constitutive NOS expressed in
endothelial cells is believed to protect against the development
of atherosclerotic lesions. Under conditions with decreased
constitutive NOS activity, iNOS might substitute the synthesis
of NO [44]. iNOS expression in vascular smooth muscle cells
and macrophages may be bene¢cial as a compensatory mech-
anism for the lack of endothelial NO synthesis, thereby pre-
venting restenosis following angioplasty or heart transplant
vasculopathy [45]. Ox-Lp(a) induced iNOS inhibition might
contribute to the development of atherosclerotic lesions by
reducing the anti-atherogenic e¡ects of NO.
iNOS gene transfer to rats and pigs has been shown to
inhibit intimal hyperplasia in response to vascular injury in
vivo. iNOS cDNA was used to express iNOS at sites of arte-
rial injury. In vivo iNOS gene transfer to injured rat carotid
arteries resulted in a near complete (s 95%) reduction in neo-
intima formation even when followed long-term to 6 weeks
post injury. This protective e¡ect was reversed by selective
iNOS inhibition [46].
The development of atherosclerotic lesions as a conse-
quence of chronic inhibition of NO production by L-
NAME, an inhibitor of both inducible and constitutive
NOS, has been reported [22,23]. Morphometric analyses re-
vealed a marked enlargement of intimal atherosclerotic areas
in aortas from L-NAME treated animals.
iNOS expression within macrophages of atherosclerotic le-
sions has been described. iNOS was not detected in normal
vessels but widespread iNOS protein staining was found in
early and advanced lesions in macrophages, foam cells, and
VSMCs of atherosclerotic vessels [32^35]. Protective e¡ects of
NO towards the oxidation of lipoproteins have been described
[47]. iNOS dependent NO release may play protective roles in
oxidative modi¢cation of LDL during the atherosclerosis pro-
cess [48]. Ox-Lp(a) induced inhibition of inducible NO syn-
thesis could result in an increased lipoprotein oxidation, there-
by establishing a vicious circle by a further decrease of NO
synthesis with concomitant increased lipoprotein oxidation.
Accumulation of monocyte derived foam cells in the arterial
intima is a major event in the development of atherogenesis.
Ox-Lp(a) and ox-LDL have been described to be potent stim-
uli of monocyte adhesion to endothelial cells [49]. Appearance
of macrophages within atherosclerotic lesions has been sup-
posed to be the consequence of an increased recruitment of
monocytes via NF-UB dependent expression of vascular endo-
thelial cell adhesion molecule 1 (VCAM-1), macrophage col-
ony stimulating factor (M-CSF) and monocyte chemoattrac-
tant protein 1 (MCP-1) by human vascular endothelial cells.
NO has been shown to inhibit VCAM-1 [25], M-CSF [50] and
MCP-1 expression [26] by inhibiting NF-UB activation. Inhi-
bition of NO synthesis by L-NMA was shown to activate NF-
UB with concomitant VCAM-1, M-CSF, and MCP-1 expres-
sion [25,26,50]. Inhibition of inducible NO synthesis by ox-
Lp(a) might in£uence macrophage accumulation within athe-
rosclerotic lesions by enhancing NF-UB dependent VCAM-1,
M-CSF, and MCP-1 expression, thereby increasing monocyte
adhesion to endothelial cells.
Furthermore, the inhibition of inducible NO synthesis by
ox-Lp(a) might initiate macrophage proliferation because NO
decreases cell proliferation by increasing the rate of apoptosis
[38]. This hints to a causative role of ox-Lp(a) induced iNOS
inhibition for the development of atherosclerotic lesions.
Numerous anti-atherogenic properties of NO in vitro have
been described. NO inhibits LDL oxidation [47], smooth
muscle cell proliferation [24], smooth muscle cell migration
[51], macrophage proliferation [38], neutrophil adhesion [52],
MCP-1 expression [26], and NF-UB activation [26,50]. Ox-
Lp(a) might contribute to the development of atherosclerotic
lesions by reducing inducible NO synthesis.
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